Developing successful central nervous system (CNS) drugs is a complex process. From conducting lengthy studies and finding hyperspecialized sites to completing patient recruitment and meeting strict regulatory guidelines – the challenges can seem endless. And for patients who urgently need these therapeutics, time is of the essence. That’s why you need a CNS CRO partner who understands the complexities at every step and across a wide range of indications.
At IQVIA Biotech, our dedicated teams have extensive experience to ensure your clinical trial is completed on time and on budget. Coupled with unparalleled data and insights, our flexible delivery model gives you the confidence you need to bring innovative CNS therapies to patients.
Patient centricity is key in study design and operationalization. At IQVIA Biotech we design the study to support the specific needs of CNS patient populations because we are driven to make a positive difference in their lives.
Clinical research in neurological disorders is making great advances in bringing new therapies to patients with unmet medical needs. However, indications such as Alzheimer’s disease and neuro-orphan diseases lack effective therapies.
IQVIA Biotech delivers full-service clinical trial solutions -- from early asset strategy and clinical development planning all the way to approval. Leverage our scientific experts, data and global resources so you can focus on what matters most: getting breakthrough treatments to patients.
Our goal is to improve the quality of life of patients with neurological diseases through advances in clinical research. Our experts walk our biotech clients through every step of the process, ensuring they know what to expect when carrying out neurology trials and how to successfully reach trial endpoints with efficient trial design and risk mitigation.
Drawing on IQVIA's unparalleled data, analytics and technologies, IQVIA Biotech brings together experience in neuroscience clinical research, data-driven capabilities, and flexible clinical solutions to help customers accelerate clinical development of innovative CNS treatments.
Connected Intelligence enables our team to manage trial complexity and increase predictability and speed.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.